A recently published study clearly demonstrated that Modufolin® administration resulted in significantly higher methylenetetrahydrofolate levels than Isovorin® administration.

Isofol Medical AB announces publication of a study comparing the concentration of folate metabolites in tumor, mucosa, and plasma of patients with colon cancer after administration of Modufolin® or Isovorin® (levo-­‐ leucovorin). The results support Isofol’s belief that Modufolin® has the potential to increase the efficacy of 5-­‐fluorouracil-­‐based chemotherapy for many patients. Results clearly demonstrated that Modufolin® administration resulted in significantly higher methylenetetrahydrofolate levels than Isovorin® administration. Isofol will continue to evaluate the potential of Modufolin® as a substitute to Isovorin® in the treatment of patients with colon cancer.

The publication entitled “A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study” is published in Cancer Chemotherapy and Pharmacology and is available online via PubMed at:http://www.ncbi.nlm.nih.gov/pubmed/25342290.

About Modufolin®
Modufolin®(chemical name [6R]-­‐5,10-­‐methylenetetrahydrofolate), is a  novel  folate-­‐based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of all clinically used  folate-­‐based  drugs  today including Leucovorin and Levoleucovorin and therefore does not require metabolic activation. This makes Modufolin® suitable for all patients irrespective of their capacity to activate folates and it is currently evaluated in clinical phase II studies.

About Isofol Medical AB
Isofol Medical is a clinical stage pharmaceutical  company  developing  novel  products  for  unmet needs within oncology. Isofol’s lead clinical candidate is  Modufolin®.  Isofol  Medical  collaborates closely with its strategic R&D partner Merck Millipore, the world’s leading manufacturer of reduced folates including Leucovorin and Levoleucovorin.

For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB

E‐mail: anders.rabbe@isofolmedical.com; Phone: +46 (0)707 646 500

Modufolin® is a registered Trademark of Merck KGaA, Darmstadt, Germany.